Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,784 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Immutep Presents Positive IMP761 Phase I Data at EULAR 2026 3 pages 147.9KB
Regulatory Filings Classification · 82% confidence The document is a corporate press release announcing the presentation of interim Phase I clinical data at a scientific conference (EULAR 2026). It does not contain financial statements, voting results, management changes, capital transactions, or other specific regulatory filings. It is not a detailed investor presentation nor a full annual/interim report, and it is not a proxy, dividend notice, or merger communication. Therefore, it falls into the catch-all category for miscellaneous regulatory or news announcements. Filing type: Regulatory Filings (RNS).
2026-06-04 English
Change in substantial holding 3 pages 179.8KB
Major Shareholding Notification Classification · 93% confidence The document is an Australian ASX Form 604 ‘Notice of change of interests of substantial holder’ under the Corporations Act, detailing voting power changes, relevant interests, and shareholding percentages. This is a notification of significant share ownership changes, matching Major Shareholding Notification (MRQ).
2026-05-28 English
Efti immune activation associated with improved survival 3 pages 215.7KB
Regulatory Filings Classification · 20% confidence The document is a corporate press release announcing clinical trial results and an upcoming poster presentation at ASCO. It contains no financial statements, no earnings figures, no management/board changes, no financing details, and no regulatory form references. It is not an investor presentation deck nor a formal report attachment notice. Therefore it does not match any specific filing category and defaults to the fallback category Regulatory Filings (RNS).
2026-05-27 English
Change in substantial holding 7 pages 186.1KB
Major Shareholding Notification Classification · 95% confidence The document is a Form 604 “Notice of change of interests of substantial holder” filed under the Corporations Act, reporting previous and current voting power and detailed changes in shareholdings by a substantial holder. This is a Major Shareholding Notification.
2026-05-26 English
Ceasing to be a substantial holder 13 pages 1.1MB
Major Shareholding Notification Classification · 92% confidence The document is a Form 605 under the Australian Corporations Act 2001, titled “Notice of ceasing to be a substantial holder,” detailing changes in relevant interests (shareholdings) of JPMorgan Chase & Co. affiliates in ImmuteP Ltd. This is a mandatory notification of changes to significant share ownership levels. Therefore, it maps to our “Major Shareholding Notification” category (MRQ).
2026-05-10 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 489.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Immutep Quarterly Activities Report & Appendix 4C Q3 FY26' and provides a detailed update on the company's clinical trial activities, financial cash flow data for the quarter ended 31 March 2026, and operational highlights. It includes substantive financial data such as cash receipts, payments for R&D, staff costs, and net cash flows from operating and investing activities. The presence of Appendix 4C, a recognized quarterly cash flow report format under ASX Listing Rules, confirms this is a quarterly financial report. The document is comprehensive and exceeds 5,000 characters, containing actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.